RT Journal Article
SR Electronic
T1 Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 781
OP 786
DO 10.21873/anticanres.16869
VO 44
IS 2
A1 SATO, RYO
A1 MATSUSHITA, YUTO
A1 TAKEMURA, AYANA
A1 SUGIYAMA, MOMOKO
A1 WATANABE, KYOHEI
A1 WATANABE, HIROMITSU
A1 TAMURA, KEITA
A1 MOTOYAMA, DAISUKE
A1 NAGATA, MASAO
A1 OTSUKA, ATSUSHI
A1 FURUSE, HIROSHI
A1 MIYAKE, HIDEAKI
YR 2024
UL http://ar.iiarjournals.org/content/44/2/781.abstract
AB Background/Aim: Although the adverse events (AEs) of drugs, such as sunitinib and axitinib, have been shown to predict treatment responses, evidence to support cabozantinib-induced AEs as predictors of responses to treatment for metastatic renal cell carcinoma (mRCC) is limited. Therefore, we herein investigated the relationship between AE profiles and progression-free survival (PFS) in patients receiving cabozantinib for previously treated mRCC. Patients and Methods: The present study retrospectively analyzed 40 patients receiving cabozantinib for previously treated mRCC between July 2020 and August 2022. PFS was estimated using the Kaplan–Meier method and the impact of several parameters, including cabozantinib-induced AEs, on PFS was investigated by a Cox proportional regression analysis. Results: The median observation period was 15 (2-29) months, during which time 31 patients (77.5%) progressed, with median PFS of 11 months. Thirty-nine patients (97.5%) developed at least one AE. Liver toxicity occurred in 16 patients (40.0%) and hand-foot syndrome, hypertension, and diarrhea in 14 each (17.5%). Only hypertension correlated with longer PFS. A multivariate analysis identified hypertension as an independent prognostic factor for PFS (p=0.049). Conclusion: These results suggest the potential of treatment-induced hypertension as a significant predictor of prolonged PFS in patients receiving cabozantinib for mRCC.